Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
SUPN Stock Forecast 2026-2027
$44.75
Current Price
$2.60B
Market Cap
Buy 5
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to SUPN Price Targets
+47.5%
To High Target of $66.00
+43.0%
To Median Target of $64.00
+22.9%
To Low Target of $55.00
SUPN Price Momentum
-3.1%
1 Week Change
-14.4%
1 Month Change
+35.0%
1 Year Change
-10.0%
Year-to-Date Change
-25.0%
From 52W High of $59.68
+45.2%
From 52W Low of $30.83
📊 TOP ANALYST CALLS
Did SUPN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Supernus is one of their latest high-conviction picks.
Latest SUPN Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, SUPN has a bullish consensus with a median price target of $64.00 (ranging from $55.00 to $66.00). The overall analyst rating is Strong Buy (9.0/10). Currently trading at $44.75, the median forecast implies a 43.0% upside. This outlook is supported by 5 Buy, 1 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Annabel Samimy at Stifel, suggesting a 22.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SUPN Analyst Ratings
5
Buy
1
Hold
0
Sell
SUPN Price Target Range
Low
$55.00
Average
$64.00
High
$66.00
Current: $44.75
Latest SUPN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SUPN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 19, 2025 | Stifel | Annabel Samimy | Hold | Maintains | $55.00 |
| Oct 29, 2025 | B of A Securities | Buy | Initiates | $N/A | |
| Oct 23, 2025 | TD Cowen | Buy | Maintains | $N/A | |
| Oct 9, 2025 | Piper Sandler | Overweight | Upgrade | $N/A | |
| Sep 30, 2025 | Cantor Fitzgerald | Overweight | Maintains | $N/A | |
| Aug 29, 2025 | Piper Sandler | Neutral | Maintains | $N/A | |
| Aug 6, 2025 | Cantor Fitzgerald | Overweight | Maintains | $N/A | |
| Feb 26, 2025 | Cantor Fitzgerald | Neutral | Reiterates | $N/A | |
| Feb 19, 2025 | Cantor Fitzgerald | Neutral | Downgrade | $N/A | |
| Sep 11, 2024 | Piper Sandler | Neutral | Downgrade | $N/A | |
| Feb 28, 2024 | Piper Sandler | Overweight | Maintains | $N/A | |
| Nov 9, 2023 | Piper Sandler | Overweight | Maintains | $N/A | |
| Oct 25, 2023 | Piper Sandler | Overweight | Maintains | $N/A | |
| May 10, 2023 | Piper Sandler | Overweight | Maintains | $N/A | |
| Jan 23, 2023 | Piper Sandler | Overweight | Maintains | $N/A | |
| Aug 31, 2022 | Piper Sandler | Overweight | Maintains | $N/A | |
| Apr 13, 2021 | Jefferies | Buy | Upgrade | $N/A | |
| Jun 16, 2020 | Piper Sandler | Overweight | Upgrade | $N/A | |
| Apr 16, 2020 | Stifel | Hold | Maintains | $N/A | |
| Nov 7, 2019 | Stifel | Hold | Downgrade | $N/A |
Supernus Pharmaceuticals Inc. (SUPN) Competitors
The following stocks are similar to Supernus based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Supernus Pharmaceuticals Inc. (SUPN) Financial Data
Supernus Pharmaceuticals Inc. has a market capitalization of $2.60B with a P/E ratio of 40.7x. The company generates $776.83M in trailing twelve-month revenue with a -3.7% profit margin.
Revenue growth is +38.6% quarter-over-quarter, while maintaining an operating margin of -3.6% and return on equity of -2.8%.
Valuation Metrics
Market Cap
$2.60B
Enterprise Value
$2.21B
P/E Ratio
40.7x
PEG Ratio
-0.5x
Price/Sales
3.3x
Growth & Margins
Revenue Growth (YoY)
+38.6%
Gross Margin
+88.7%
Operating Margin
-3.6%
Net Margin
-3.7%
EPS Growth
+38.6%
Financial Health
Cash/Price Ratio
+14.8%
Current Ratio
2.0x
Debt/Equity
3.8x
ROE
-2.8%
ROA
+1.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Supernus Pharmaceuticals Inc. (SUPN) Business Model
About Supernus Pharmaceuticals Inc.
What They Do
Develops treatments for central nervous system disorders.
Business Model
Supernus Pharmaceuticals generates revenue through the development and commercialization of proprietary pharmaceutical products, alongside strategic partnerships that enhance its medication pipeline. The company focuses specifically on treatments for CNS disorders, allowing it to address significant unmet medical needs in neurology and psychiatry.
Additional Information
With a strong emphasis on research and development, Supernus is recognized for its contributions to the pharmaceutical industry, particularly in improving the management of conditions such as epilepsy, migraine, ADHD, and bipolar disorder. Their commitment to innovation is supported by extensive clinical trials and regulatory expertise, positioning them as a key player in advancing therapeutic solutions.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
674
CEO
Mr. Jack A. Khattar M.B.A.
Country
United States
IPO Year
2012
Website
www.supernus.comSupernus Pharmaceuticals Inc. (SUPN) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Should You Buy, Sell or Hold BIIB Stock After it Rises Almost 12% YTD?
Biogen climbs 11.5% YTD as new drugs, pipeline progress and M&A activity fuel confidence in Biogen???s multiyear turnaround.
May 29, 2026
By Kinjel Shah
Analyst Blog
Latest News
Quick Summary
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) announced management will participate in June investor conferences, focusing on CNS disease treatments.
Why It Matters
Supernus Pharmaceuticals' participation in investor conferences may signal strategic initiatives, potentially influencing stock valuation and investor sentiment regarding its CNS product pipeline.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Supernus Pharmaceuticals (SUPN) presented at the Bank of America Global Healthcare Conference 2026, providing insights into its operations and future plans.
Why It Matters
Supernus Pharmaceuticals' presentation at a major healthcare conference could influence investor sentiment and stock performance, showcasing its strategies, pipeline developments, and market positioning.
Source: Seeking Alpha
Market Sentiment:
Neutral
Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference
1 month ago
Quick Summary
Supernus Pharmaceuticals CEO Jack A. Khattar will speak at the Bank of America 2026 Health Care Conference on May 12, 2026, at 3:40 p.m. PT in Las Vegas.
Why It Matters
Supernus Pharmaceuticals' CEO will discuss the company's strategies at a major health care conference, potentially impacting investor sentiment and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Supernus Pharmaceuticals, Inc. (SUPN) held its Q1 2026 earnings call, providing updates on financial performance and business developments. Further details are available in the full transcript.
Why It Matters
Supernus Pharmaceuticals' Q1 2026 earnings call reveals financial performance and future prospects, impacting stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Supernus Pharmaceuticals (Nasdaq: SUPN) reported its first-quarter 2026 financial results and company developments, focusing on CNS disease treatments.
Why It Matters
Supernus Pharmaceuticals' Q1 2026 financial results and developments may impact stock performance, reflecting its growth potential and market position in CNS treatments.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Supernus (SUPN) reported its Q1 2026 financial results, with key metrics available for comparison against Wall Street estimates and prior year performance.
Why It Matters
Supernus' quarterly performance against Wall Street estimates and prior year results can influence stock valuation, indicating growth potential or challenges ahead.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Frequently Asked Questions About SUPN Stock
What is Supernus Pharmaceuticals Inc.'s (SUPN) stock forecast for 2026?
Based on our analysis of 2 Wall Street analysts, Supernus Pharmaceuticals Inc. (SUPN) has a median price target of $64.00. The highest price target is $66.00 and the lowest is $55.00.
Is SUPN stock a good investment in 2026?
According to current analyst ratings, SUPN has 5 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $44.75. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SUPN stock?
Wall Street analysts predict SUPN stock could reach $64.00 in the next 12 months. This represents a 43.0% increase from the current price of $44.75. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Supernus Pharmaceuticals Inc.'s business model?
Supernus Pharmaceuticals generates revenue through the development and commercialization of proprietary pharmaceutical products, alongside strategic partnerships that enhance its medication pipeline. The company focuses specifically on treatments for CNS disorders, allowing it to address significant unmet medical needs in neurology and psychiatry.
What is the highest forecasted price for SUPN Supernus Pharmaceuticals Inc.?
The highest price target for SUPN is $66.00 from at , which represents a 47.5% increase from the current price of $44.75.
What is the lowest forecasted price for SUPN Supernus Pharmaceuticals Inc.?
The lowest price target for SUPN is $55.00 from Annabel Samimy at Stifel, which represents a 22.9% increase from the current price of $44.75.
What is the overall SUPN consensus from analysts for Supernus Pharmaceuticals Inc.?
The overall analyst consensus for SUPN is bullish. Out of 2 Wall Street analysts, 5 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $64.00.
How accurate are SUPN stock price projections?
Stock price projections, including those for Supernus Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 7, 2026 6:53 PM UTC